Workflow
Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial
Harmony BiosciencesHarmony Biosciences(US:HRMY) Reuters·2025-09-24 20:33

公司药物临床试验结果 - 实验性药物治疗罕见遗传病未达到三期临床试验主要目标 [1] - 消息公布后公司股价在盘前交易中下跌8% [1]